In-Depth Research On:
Neurocrine Biosciences, Inc. (NBIX)

Sign Up Now to Download a Free Research Report on NBIX

Sign-Up to Get the Equity Report on this Company Plus Exclusive Access to Our Winning Newsletter Alerts

Select your areas of interest / would you like to receive the newsletter?




Download Adobe Reader Having problems viewing PDF files? Download Adobe Reader.

Neurocrine Biosciences, Inc.

Neurocrine Biosciences shares soared 89.69 percent to close at $18.51 a share Tuesday. The stock traded between $15.20 and $18.62 on volume of 18.95 million shares traded. The company reported positive results from a Phase II study of NBI-98854 for the treatment of tardive dyskinesia. Shares of Neurocrine Biosciences have gained approximately 120.0 percent in the past year.

Going forward ... (see research report)


RESEARCH REPORT ON NBIX
Download Free Report Now


Preview Pages of Actual Research Report

Download Adobe Reader Having problems viewing PDF files? Download Adobe Reader. Research Report on    Research Report on    Research Report on    

Research Report on    Research Report on    Research Report on